Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 2 (2)

Trial Status

Not Yet Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT07483554Phase 2Not Yet RecruitingPrimary

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

NCT07483567Phase 2Not Yet RecruitingPrimary

IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Showing all 2 trials

Research Network

Activity Timeline